Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.98 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.98 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | RXRA | P19793 | 1/20 | 0.98 |
| ▸ | CCKAR | P32238 | 1/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL1147657 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6250394 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL4620256 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL1147653 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL41662 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL41664 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL5072556 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6270543 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL246750 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL28166565 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240175032-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | SIRNAOMICS, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4359377-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-05-01 | — | — | EP | disclosed |
| EP-4347823-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230104125-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230068339-A1 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230019098-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | RISEN (SHANGHAI) MEDICINAL TECH CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20230002772-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-01-05 | — | — | US | disclosed |
| WO-2022266753-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-12-29 | — | — | WO | disclosed |
| EP-4107265-A1 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022256395-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-2001484-A2 | METHODS AND COMPOSITIONS FOR TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | The President and Fellows of Harvard College (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1940391-A1 | STABILIZED EXTENDED RELEASE PHARMECEUTICAL COMPOSITIONS COMPRISING AN HMG-COA REDUCTASE INHIBITOR | Orbus Pharma Inc. (CA) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007111992-A2 | METHODS AND COMPOSITIONS FOR TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1799263-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | The President and Fellows of Harvard College (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007016757-A1 | STABILIZED EXTENDED RELEASE PHARMECEUTICAL COMPOSITIONS COMPRISING AN HMG-COA REDUCTASE INHIBITOR | ORBUS PHARMA INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006085338-A2 | NOVEL POLYMORPHIC FORMS OF FLUVASTATIN SODIUM AND PROCESS FOR PREPARING THE SAME | JUBILANT ORGANOSYS LIMITED (IN) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006031931-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006030304-A2 | NOVEL FORMS OF FLUVASTATIN SODIUM, PROCESSES FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-23 | — | — | WO | disclosed |
| US-20060034831-A1 | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors | WYETH | 2006-02-16 | — | — | US | disclosed |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230068339-A1 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | APOB, RNASE1, APOL1 | HMGCR 62/4885CYP2C9 4808/4885SIRT6 3896/4885 |
| US-20230104125-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | PCSK9, PCSK7, PCSK6 | HMGCR 13/4885CYP2C9 4714/4885SIRT6 1268/4885 |
| US-20240175032-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | PCSK9, PCSK6, LDLR | HMGCR 24/4885CYP2C9 4115/4885SIRT6 626/4885 |
| US-20060034831-A1 | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors | DPP8, IGFBP1, IGFBP5 | HMGCR 634/4885CYP2C9 3654/4885SIRT6 835/4885 |
| US-20230002772-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PCSK9, LDLR, RNASE1 | HMGCR 15/4885CYP2C9 4846/4885SIRT6 2717/4885 |
| US-20230019098-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | PLK1, BRDT, BCR | HMGCR 1923/4885CYP2C9 3506/4885SIRT6 2013/4885 |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | PTPN6, PTPN1, PNLIP | HMGCR 53/4885CYP2C9 1661/4885SIRT6 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.